carboplatin + ifosfamide combination

The carboplatin + ifosfamide combination is a chemotherapy regimen used to treat various malignancies. This combination has been studied extensively and is often administered with other agents such as etoposide (forming ICE) or with rituximab (forming R-ICE). ## Mechanism and Clinical Use Carboplatin and ifosfamide are both chemotherapeutic agents that destroy rapidly dividing cells, particularly cancer cells[5]. They appear to have overlapping renal toxicity, but can be combined at approximately 75-80% of their single-agent maximum-tolerated doses with acceptable non-hematologic toxicity[2]. The combination has shown promising results in treating: - Sarcomas - Germ cell tumors - Lymphomas (particularly when combined with etoposide as ICE) - Breast cancer - Lung cancer ## Administration and Dosing The carboplatin + ifosfamide combination is typically administered intravenously. Ifosfamide is often given with mesna to prevent bladder irritation and bleeding[5]. The combination may be given in various schedules, with a common approach being: - Carboplatin: 300-400 mg/m² on day 1 - Ifosfamide: 1.25-5 g/m² over 1-3 days - Treatment cycles typically last 21 days (3 weeks) ## Side Effects Common side effects include: - Neutropenia (often severe, grade 4) - Thrombocytopenia - Leukopenic fever - Alopecia (universal) - Renal toxicity (dose-limiting at higher doses) - Transient hematuria - Somnolence and confusion (associated with rising creatinine) Most patients receive granulocyte colony-stimulating factor (G-CSF) support to manage bone marrow suppression[1][5]. ## Clinical Evidence In phase I/II studies, the carboplatin + ifosfamide combination has demonstrated: - Acceptable toxicity profile when properly dosed - Encouraging response rates in heavily pretreated patients - Complete and partial responses in sarcoma and germ cell carcinoma patients[2] - Potential as a core combination for further studies in sarcoma, germ cell, ovarian, and lung carcinomas[2] When combined with etoposide (ICE) or rituximab plus etoposide (R-ICE), this regimen is particularly effective for relapsed or refractory non-Hodgkin lymphoma, often used as salvage therapy before stem cell transplantation[3][6].